HC Wainwright Cuts TuHURA Biosciences (NASDAQ:HURA) Price Target to $12.00

TuHURA Biosciences (NASDAQ:HURA) had its target price cut by equities researchers at HC Wainwright from $13.00 to $12.00 in a report released on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 244.83% from the company’s previous close.

Several other analysts have also recently commented on HURA. RODMAN&RENSHAW upgraded TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th. Rodman & Renshaw started coverage on shares of TuHURA Biosciences in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective on the stock.

TuHURA Biosciences Stock Up 19.6 %

Shares of HURA opened at $3.48 on Thursday. The stock has a 50-day moving average price of $3.46. TuHURA Biosciences has a 12-month low of $1.80 and a 12-month high of $7.93.

Hedge Funds Weigh In On TuHURA Biosciences

Institutional investors have recently added to or reduced their stakes in the business. Accent Capital Management LLC bought a new stake in shares of TuHURA Biosciences in the 4th quarter valued at $29,000. TT Capital Management LLC bought a new position in shares of TuHURA Biosciences during the 4th quarter worth about $41,000. Jefferies Financial Group Inc. acquired a new stake in shares of TuHURA Biosciences in the 4th quarter valued at about $54,000. Bank of America Corp DE bought a new stake in TuHURA Biosciences in the 4th quarter valued at about $59,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in TuHURA Biosciences during the 4th quarter worth approximately $61,000. 0.62% of the stock is owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.